ABCC8
ENSG00000006071
Target class
Transporter
Chromosome
11
Approved drugs
10
Clinical candidates (approved and in development)
15
- Approved drugs
- 10
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 15
- Chemical probe available
- Yes
- Target name
- ABCC8
- Gene name
- ATP binding cassette subfamily C member 8
- Gene symbol
- ABCC8
- Protein name
- ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1)
- HI
- PHHI
- SUR1
- MRP8
- ABC36
- HHF1
- TNDM2
- SUR
- HRINS
- Gene biotype
- Protein coding
- Gene family
- ATP binding cassette subfamily C
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 32
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 125.94
- Tissue specificity (Gini)
- 0.793
- Tissue specificity (tau)
- 0.942
- KEGG gene identifiers
- hsa:6833
- Protein interaction confidence
- 0.855273
- Protein interaction partners
- 22
- R-HSA-1296025
- R-HSA-422356
- R-HSA-5683177
- End position
- 17476894
- Start position
- 17392498
- Chromosome
- 11
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- Cytosol
- Golgi apparatus
- Nucleoli
- Principal piece
- PubMed 24814349
- PubMed 29286281
- PubMed 34815345
- Tissue specificity (tau)
- 0.941915
- Expression inequality (Gini)
- 0.793421
Expression in transcripts per million
- Brain - Cerebellum
- 125.94
- Brain - Cerebellar Hemisphere
- 106.12
- Pituitary
- 74.06
- Brain - Cortex
- 30.02
- Brain - Frontal Cortex (BA9)
- 22.18
Expression in transcripts per million
- Brain - Cerebellum125.94
- Brain - Cerebellar Hemisphere106.12
- Pituitary74.06
- Brain - Cortex30.02
- Brain - Frontal Cortex (BA9)22.18
- Brain - Anterior cingulate cortex (BA24)14.55
- Brain - Nucleus accumbens (basal ganglia)10.19
- Brain - Hypothalamus10.12
- Pancreas10.09
- Brain - Caudate (basal ganglia)9.76
- Brain - Spinal cord (cervical c-1)9.75
- Cervix - Ectocervix8.82
- Brain - Hippocampus8.25
- Thyroid7.08
- Brain - Amygdala6.94
- Brain - Putamen (basal ganglia)6.89
- Stomach6.49
- Lung5.59
- Brain - Substantia nigra5.38
- Nerve - Tibial5.19
- Cervix - Endocervix4.32
- Prostate3.43
- Uterus2.26
- Vagina2.05
- Fallopian Tube1.7
And 29 more, listed on the interactive page.
- GO:0006813
- GO:0050796
- GO:0005886
- GO:0008282
- GO:0005267
- GO:0005524
- GO:0015272
- GO:0019829
- GO:0044325
abnormal pulse
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: abnormal pulse
- pancreas
- renal
- cardiovascular
PubMed 28216264increased/decreased blood glucose
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased blood glucose
- pancreas
- renal
- cardiovascular
PubMed 28216264increased urinary sodium excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased heart rate
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased blood glucose
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased blood glucose
- pancreas
- renal
- cardiovascular
PubMed 28216264cardiac lesions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cardiac lesions
- pancreas
- renal
- cardiovascular
PubMed 28216264increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart rate
- pancreas
- renal
- cardiovascular
PubMed 28216264cardiac arrhythmia
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cardiac arrhythmia
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- pancreas
- renal
- cardiovascular
PubMed 28216264atrioventricular block
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: atrioventricular block
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased blood insulin
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood insulin
- pancreas
- renal
- cardiovascular
PubMed 28216264increased blood insulin
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased blood insulin
- pancreas
- renal
- cardiovascular
PubMed 28216264increased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urine excretion
- pancreas
- renal
- cardiovascular
PubMed 28216264
Related records
Trials (698)
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
- A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
- A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
- A Comparison Between Two Oral Hypoglycemics - Metformin and Glybenclamide for the Treatment of Gestational Diabetes Mellitus
- A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
- A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
- A Drug Interaction Study of LY3871801 in Healthy Participants
- A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.
- A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Drugs (15)
- Acetohexamide Sulfonylurea receptor 1, Kir6.2 blocker
- Chlorpropamide Sulfonylurea receptor 1, Kir6.2 blocker
- Gliclazide Sulfonylurea receptor 1, Kir6.2 blocker
- Glimepiride Sulfonylurea receptor 1, Kir6.2 blocker
- Glipizide Sulfonylurea receptor 1, Kir6.2 blocker
- Glyburide Sulfonylurea receptor 1, Kir6.2 blocker
- Mitiglinide Sulfonylurea receptor 1, Kir6.2 blocker
- Mitiglinide calcium dihydrate Sulfonylurea receptor 1, Kir6.2 blocker
- Naminidil Sulfonylurea receptors; K-ATP channels opener
- Nateglinide Sulfonylurea receptor 1, Kir6.2 blocker
- Repaglinide Sulfonylurea receptor 1, Kir6.2 blocker
- Sarakalim Sulfonylurea receptors; K-ATP channels opener
- Tolazamide Sulfonylurea receptor 1, Kir6.2 blocker
- Tolbutamide Sulfonylurea receptor 1, Kir6.2 blocker
- Tolbutamide sodium Sulfonylurea receptor 1, Kir6.2 blocker